持续性孤立性C3低补体血症是狼疮性肾炎终末期肾病的强预测因子
该研究回顾性随访197例增生性狼疮性肾炎患者(其中51例存在持续性孤立性C3低补体血症),中位随访4.5年,发现PI-LowC3与复合终点(终末期肾病或死亡)风险升高相关(HR 2.46,95%CI 1.22-4.99,P=0.012),校正竞争风险后终末期肾病风险亦显著升高(校正HR 3.41,95%CI 1.31-8.88,P=0.012)。
要点
- 肾活检后6个月持续性孤立性C3低补体血症与增生性狼疮性肾炎患者终末期肾病或死亡风险升高相关。
- PI-LowC3患者复合终点风险HR 2.46(95%CI 1.22-4.99,P=0.012),终末期肾病校正HR 3.41(95%CI 1.31-8.88,P=0.012)。
- 作者认为PI-LowC3可作为低成本易获取的生物标志物,为补体阻断试验提供依据。
核心结论
- 持续性孤立性C3低补体血症与增生性狼疮性肾炎患者死亡或终末期肾病风险升高独立相关。
- 作者认为PI-LowC3可作为低成本易获取的生物标志物,使临床医生能在疾病早期调整治疗策略,并为该高危亚组患者的补体阻断试验提供依据。
研究设计与样本
- 回顾性随访197例增生性狼疮性肾炎患者,其中51例存在持续性孤立性C3低补体血症,中位随访4.5年(四分位距1.9-9.0年)。
主要发现
- 随访期间11例死亡,22例达到终末期肾病。
- 校正年龄、性别、种族、高血压、霉酚酸酯或环磷酰胺使用后,PI-LowC3与复合终点终末期肾病或死亡的HR为2.46(95%CI 1.22-4.99,P=0.012)。
- 在联合纵向-生存多重回归模型中控制时变估算肾小球滤过率测量值后,结果仍得到确认。
- 考虑死亡竞争风险后,PI-LowC3患者终末期肾病风险显著升高(校正HR 3.41,95%CI 1.31-8.88,P=0.012)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Proliferative lupus nephritis (LN) progresses to end-stage kidney disease (ESKD) in roughly 10% of the cases despite treatment. Other than achieving <0.8 g/24h proteinuria at 12 months after treatment, early biomarkers predicting ESKD or death are lacking. Recent studies encompassing not only LN have highlighted the central role of the alternative complement pathway (ACP), with or without histological evidence of thrombotic microangiopathy (TMA), as a key promotor of renal death. METHODS: We assessed whether persistent isolated C3 hypocomplementemia (PI-LowC3), that is not accompanied by C4 hypocomplementemia, 6 months after kidney biopsy, is associated with an increased risk of death or ESKD in proliferative LN. RESULTS: We retrospectively followed-up 197 patients with proliferative LN (51 with PI-LowC3) for a median of 4.5 years (interquartile-range: 1.9-9.0), 11 of whom died and 22 reached ESKD. After adjusting for age, gender, ethnicity, hypertension, mycophenolate, or cyclophosphamide use, PI-LowC3 was associated with a hazard ratio [HR] of the composite outcome ESKD or death of 2.46 (95% confidence interval [CI]: 1.22-4.99, P = 0.012). These results were confirmed even after controlling for time-varying estimated glomerular filtration rate (eGFR) measurements in joint longitudinal-survival multiple regression models. After accounting for the competing risk of death, PI-LowC3 patients showed a strikingly increased risk of ESKD (adjusted HR 3.41, 95% CI: 1.31-8.88, P = 0.012). CONCLUSION: Our findings support the use of PI-LowC3 as a low-cost readily available biomarker, allowing clinicians to modify treatment strategies early in the course of disease and offering a rationale for complement blockade trials in this particularly at-risk subgroup of LN patients.
引用
- Rossi GM, Maggiore U, Peyronel F, et al. Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis. Kidney Int Rep. 2022. PMID: 36506236. doi:10.1016/j.ekir.2022.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。